4 Key Takeaways From Eli Lilly's Earnings

Eli Lilly (LLY) shares soared Thursday, after the company's second-quarter earnings surpassed expectations on booming demand for its weight-loss drugs and executives provided updates on production capacity and more. Demand for Weight-Loss Drugs Fuels Growth Sales of Eli Lilly weight-loss drug Mounjaro more than tripled year-over-year to $3.09 billion in the quarter. Sales of Zepbound, another weight-loss drug, have reached $1 billion in less than a year since the drug received FDA approval in November 2 ...